Risk Disclaimer
The positions in this portfolio are incredibly risky and extremely volatile.
No one at Get Irked is a professional financial adviser (or a doctor), so consult with your own financial adviser to see if any of these positions fit your risk profile (and stomach).
March 8, 2019
Click any chart for an enlarged version
Highlights from the Week
Biggest Winner: Aurora Cannabis (ACB)
Aurora’s (ACB) this week’s biggest winners after analyst reports announced ACB as the darling of the U.S. cannabis space. Despite partnerships between Cronos (CRON) and big tobacco, analysts believe ACB is where it’s at, raising their price targets on the stock to $14.00 per share and allowing ACB to finish the week up +5.59% where the S&P 500 dropped -2.16%.
Biggest Loser: Gossamer Biopharma (GOSS)
IPOs are notoriously volatile, so it’s no surprise that GOSS got slammed this week after an outstanding performance last week. Fresh IPOs are still seeking price levels, so expect extreme volatility in GOSS next week, too. Who knows? Maybe it could be next week’s biggest winner?
This Week’s Trades
Aurora Cannabis (ACB)
Aurora (ACB) popped after analysts named it one of their favorite cannabis stocks leading us to take some profits when the stock touched $8.24, lowering our per-share cost to $4.95. ACB closed the week at $7.75 with our position up +56.62%.
BiliBili (BILI) *New Position*
BiliBili (BILI) is China’s YouTube, a popular video and social media site among China’s millenials. After reporting a good quarter, BILI started to turn over during the market sell-off so we opened a position at $17.68. BILI closed the week at $17.94 with our position up +1.47%.
Gossamer Biopharma (GOSS)
GOSS rolled over with the rest of the market, giving us the opportunity to build on our position and lower our per-share cost, buying at $19.13. GOSS closed the week at $19.73 with our position -1.22%.
Insys Therapeutics (INSY)
We took some profits in Insys (INSY) during Monday’s selloff when INSY couldn’t hold a key support level, selling a small amount of our position at $6.08, lowering our per-share cost to $1.85. INSY missed on earnings but gave decent guidance, closing the week down slightly during the selloff at $5.63 with our position up +205.31%.
TransEnterix (TRXC)
TransEnterix (TRXC) has fallen back into its old trading range, dipping below one of our key target price points leading us to add to the position at $2.44 and $2.36. TRXC closed the week at $2.41 with our position -2.31%.
Questions?
As always, If you have questions about how we’re playing different positions or anything at all, really, feel free to leave a comment below!
